6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting

Producción científica: Contribución a una revista › Carta al editor › revisión exhaustiva

5 Citas (Scopus)

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

@article{30711f23534e4b65872adb2fcf6e90b2,

title = "6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting",

author = "Naysha Becerra-Chauca and Wendy Nieto-Gutierrez and Alvaro Taype-Rondan",

year = "2022",

month = mar,

doi = "10.1016/S1470-2045(22)00060-2",

language = "Ingl{\'e}s",

volume = "23",

pages = "e100",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting

AU - Becerra-Chauca, Naysha

AU - Nieto-Gutierrez, Wendy

AU - Taype-Rondan, Alvaro

PY - 2022/3

Y1 - 2022/3

UR - https://www.scopus.com/pages/publications/85125308371

U2 - 10.1016/S1470-2045(22)00060-2

DO - 10.1016/S1470-2045(22)00060-2

M3 - Carta al editor

AN - SCOPUS:85125308371

SN - 1470-2045

VL - 23

SP - e100

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -